BioNTech SE (BNTX) Stock
BNTX Key Statistics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
CEO: Ugur Sahin. Company website
BNTX — Frequently Asked Questions
What is the BNTX stock price today?
BioNTech SE (BNTX) trades at $96.06, down 2.64% on the day, as of Sep 20, 2026 15:01 UTC.
What is BioNTech SE's market cap?
BioNTech SE has a market capitalisation of $24.13B, calculated from the live BNTX share price and shares outstanding.
What is the P/E ratio of BNTX?
BNTX has no meaningful price-to-earnings ratio: BioNTech SE lost $6.73 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does BioNTech SE make?
BioNTech SE generated revenue of $2.64B over the trailing twelve months, which puts the stock at 9.13 times sales.
What is the 52-week range for BNTX?
BNTX has traded between $79.52 and $123.80 over the past 52 weeks, and the last price is 22.4% below that high.
Is BioNTech SE profitable?
No. BioNTech SE is loss-making, with a net margin of -64.25% over the trailing twelve months.
What is the analyst price target for BNTX?
Wall Street analysts rate BNTX Buy, with an average price target of $118.20, 23.0% above the current price.
What sector is BioNTech SE in?
BioNTech SE is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in DE.
Who is the CEO of BioNTech SE?
Ugur Sahin is the chief executive of BioNTech SE, which employs 7,807 people.
Where can I track BNTX in real time?
QFI Terminal shows BNTX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See BNTX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open BNTX in Terminal See plans